Abstract：
Non-tuberculous mycobacterial infections are gradually increasing worldwide, with slow-growing mycobacteria such as Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium kansasii accounting for the majority of cases. The use of tetracyclines has received renewed attention in recent years, and this study was designed to investigate the antibacterial activity of omadacycline, eravacycline, tigecycline, sarecycline, minocycline and doxycycline against M. avium, M. intracellulare and M. kansasii. Susceptibility testing of six tetracyclines was conducted against M. avium, M. intracellulare and M. kansasii isolates, and all the clinical isolates were collected from January 2012 to December 2018. All six agents exhibited poor antibacterial activity against slowly growing mycobacteria (SGM) isolates of three subspecies with MIC50 and MIC90 ≥8 μg/mL. M. intracellulare and M. kansasii had lower resistance rates to omadacycline than the other five drugs. The severe resistance of SGM to tetracycline suggests that developing tetracycline-class antibiotics needs to overcome existing resistance mechanisms.
摘要：
非结核分枝杆菌感染在全球范围内逐渐增多,生长缓慢的分枝杆菌，如鸟分枝杆菌，细胞内分枝杆菌和kansasii分枝杆菌占大多数病例。四环素类药物的使用近年来重新受到关注,本研究旨在研究奥马环素的抗菌活性，eravacycline,替加环素,sareccine,米诺环素和多西环素对鸟分枝杆菌，M.细胞内和M.kansasii。进行了六种四环素对鸟分枝杆菌的药敏试验,细胞内分离菌和Kansasii分离菌，所有临床分离株均于2012年1月至2018年12月收集.所有六种药物对MIC50和MIC90≥8μg/mL的三个亚种的缓慢生长的分枝杆菌（SGM）分离株的抗菌活性均较差。胞内分枝杆菌和kansasii对奥马环素的耐药率低于其他五种药物。SGM对四环素的严重耐药性表明开发四环素类抗生素需要克服现有的耐药机制。
